Skip to main content
. 2022 Mar 28;27(Suppl 1):S13–S14. doi: 10.1093/oncolo/oyac011

Table 2.

Median progression-free survival by duration of prior CDK4/6 inhibitor therapy

Endpoints ≤6 months >6 months HR (95% CI)
Cohort A (n = 26) (n = 94) 0.51 (0.29-0.89)
 PFS events 57.7% 79.8%
 Median PFS 12.0 months 6.2 months
Cohort B (n = 30) (n = 83) 0.72 (0.45-1.18)
 PFS events 76.7% 77.1%
 Median PFS 5.9 months 5.6 months